Featured 13F manager
Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site · 2021 Q3–2026 Q2
- $21.7B
- 77 Positions
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Portfolio
top 5 29.9% · top 10 44.0%
- RVMD - Revolution Medicines 11.7%
- EA - Electronic Arts 7.5%
- BBIO - Bridgebio Pharma 3.7%
- PTGX - Protagonist Therapeutics 3.6%
- EXEL - Exelixis 3.4%
- LQDA - Liquidia 3.1%
- AMZN - Amazon 2.9%
- LNTH - Lantheus 2.9%
- NTRA - Natera 2.8%
- UNH - Unitedhealth Group 2.4%
- TMO - Thermo Fisher Scientific 2.4%
- ROIV - Roivant Sciences 2.3%
- Other 51.3%
AUM over time
Book
| Pioneer Nat Res | 4.18% | New | 3,520,000 | $262.50 | $924M | +3,520,000 | +$924M |
| UNH - Unitedhealth Group | 3.81% | Add +41.5% | 1,701,410 | $494.70 | $842M | +498,810 | +$209M |
| IQV - IQVIA | 3.24% | Reduce −4.2% | 2,836,162 | $252.89 | $717M | −124,870 | +$32M |
| EXEL - Exelixis | 2.86% | Add +0.2% | 26,678,500 | $23.73 | $633M | +44,000 | −$6M |
| CRM - Salesforce | 2.66% | Add +1.4% | 1,952,168 | $301.18 | $588M | +26,430 | +$81M |
| ARMK - Aramark | 2.62% | Add +5.5% | 17,822,937 | $32.52 | $580M | +923,683 | +$105M |
| NDAQ - Nasdaq | 2.41% | Add +28.4% | 8,436,719 | $63.10 | $532M | +1,866,219 | +$150M |
| MSFT - Microsoft | 2.30% | Reduce −9.5% | 1,211,458 | $420.72 | $510M | −127,120 | +$6M |
| GOOG - Alphabet · CL C | 2.30% | Add +6.4% | 3,337,950 | $152.26 | $508M | +199,410 | +$66M |
| TRU - Transunion | 2.29% | Reduce −30.4% | 6,351,256 | $79.80 | $507M | −2,771,700 | −$120M |
| NYT - New York Times · CL A | 2.19% | Add +18.1% | 11,188,059 | $43.22 | $484M | +1,711,268 | +$19M |
| TMO - Thermo Fisher Scientific | 2.10% | Reduce −33.7% | 797,416 | $581.21 | $463M | −405,715 | −$175M |
| WAB - Wabtec | 1.95% | Reduce −24.9% | 2,956,398 | $145.68 | $431M | −981,910 | −$69M |
| CBRE - CBRE Group · CL A | 1.84% | Reduce −1.5% | 4,184,030 | $97.24 | $407M | −61,970 | +$12M |
| NTRA - Natera | 1.62% | Add +13.0% | 3,927,683 | $91.46 | $359M | +452,800 | +$142M |
| INTU - Intuit | 1.58% | Add +0.8% | 537,078 | $650.00 | $349M | +4,078 | +$16M |
| SPGI - S&P Global | 1.53% | Reduce −10.1% | 793,844 | $425.45 | $338M | −88,751 | −$51M |
| Sarepta Therapeutics | 1.44% | Add +102.8% | 2,453,500 | $129.46 | $318M | +1,243,427 | +$201M |
| BSX - Boston Scientific | 1.42% | Reduce −21.0% | 4,596,657 | $68.49 | $315M | −1,223,600 | −$22M |
| ADI - Analog Devices | 1.38% | Add +3.3% | 1,537,990 | $197.79 | $304M | +48,890 | +$9M |
| NOW - Servicenow | 1.36% | Reduce −6.2% | 395,088 | $762.40 | $301M | −26,162 | +$4M |
| ABNB - Airbnb · CL A | 1.20% | New | 1,608,220 | $164.96 | $265M | +1,608,220 | +$265M |
| SHW - Sherwin Williams | 1.18% | Reduce −9.4% | 753,830 | $347.33 | $262M | −78,262 | +$2M |
| CSGP - Costar Group | 1.13% | Reduce −16.9% | 2,594,356 | $96.60 | $251M | −527,000 | −$22M |
| MA - Mastercard · CL A | 1.12% | Reduce −17.2% | 513,161 | $481.57 | $247M | −106,310 | −$17M |
| RVMD - Revolution Medicines | 1.09% | Add +11.4% | 7,507,872 | $32.23 | $242M | +771,018 | +$49M |
| HWM - Howmet Aerospace | 1.06% | Reduce −27.7% | 3,410,759 | $68.43 | $233M | −1,305,268 | −$22M |
| Masimo | 0.99% | Add +13.6% | 1,489,563 | $146.85 | $219M | +177,914 | +$65M |
| AON - AON PLC · CL A | 0.95% | New | 632,000 | $333.72 | $211M | +632,000 | +$211M |
| CNC - Centene Del | 0.93% | Reduce −36.9% | 2,607,875 | $78.48 | $205M | −1,524,200 | −$102M |
| YMM - Full Truck Alliance | 0.86% | Reduce −31.2% | 26,285,059 | $7.27 | $191M | −11,905,436 | −$77M |
| V - VISA · CL A | 0.86% | Reduce −14.7% | 680,850 | $279.08 | $190M | −117,260 | −$18M |
| PTGX - Protagonist Therapeutics | 0.75% | Add +0.1% | 5,738,973 | $28.93 | $166M | +4,543 | +$35M |
| AGIO - Agios Pharmaceuticals | 0.74% | Add +34.1% | 5,590,602 | $29.24 | $163M | +1,423,000 | +$71M |
| BEAM - Beam Therapeutics | 0.67% | Add +9.9% | 4,511,753 | $33.04 | $149M | +406,000 | +$37M |
| INSP - Inspire Med Sys | 0.61% | Reduce −26.7% | 626,854 | $214.79 | $135M | −228,242 | −$39M |
| Holding | 0.57% | Add +271.1% | 5,790,500 | $21.60 | $125M | +4,230,000 | +$116M |
| AZNN — | 0.45% | Reduce −61.8% | 1,459,718 | $67.75 | $99M | −2,364,573 | −$159M |
| VSTS - Vestis | 0.43% | Reduce −10.1% | 4,914,753 | $19.27 | $95M | −555,000 | −$21M |
| LNTH - Lantheus | 0.42% | Add +595.3% | 1,483,227 | $62.24 | $92M | +1,269,900 | +$79M |
| GBTC - Grayscale Bitcoin Tr Btc | 0.39% | New | 1,349,077 | $63.17 | $85M | +1,349,077 | +$85M |
| COR - Cencora | 0.37% | Add +97.6% | 334,000 | $242.99 | $81M | +165,000 | +$46M |
| THC - Tenet Healthcare | 0.30% | Add +70.1% | 637,442 | $105.11 | $67M | +262,600 | +$39M |
| SIMO - Silicon Motion Technology | 0.30% | Add +247.0% | 855,449 | $76.94 | $66M | +608,949 | +$51M |
| BEKE - KE | 0.29% | Reduce −0.4% | 4,740,833 | $13.73 | $65M | −17,667 | −$12M |
| ICLR - ICON | 0.27% | New | 179,700 | $335.95 | $60M | +179,700 | +$60M |
| EDU — | 0.24% | Add +4630.8% | 615,000 | $86.82 | $53M | +602,000 | +$52M |
| BHVN - Biohaven | 0.20% | Add +6.5% | 799,000 | $54.69 | $44M | +49,000 | +$12M |
| ENTA - Enanta Pharmaceuticals | 0.17% | Add +3.5% | 2,095,000 | $17.46 | $37M | +70,000 | +$18M |
| EVH - Evolent Health · CL A | 0.15% | Reduce −52.1% | 1,037,331 | $32.79 | $34M | −1,126,578 | −$37M |
| IONS - Ionis Pharmaceuticals | 0.14% | Reduce −52.8% | 734,000 | $43.35 | $32M | −821,020 | −$47M |
| LQDA - Liquidia | 0.14% | New | 2,055,000 | $14.75 | $30M | +2,055,000 | +$30M |
| HIMS - Hims & Hers Health · CL A | 0.12% | Add +3890.5% | 1,676,000 | $15.47 | $26M | +1,634,000 | +$26M |
| PCVX - Vaxcyte | 0.12% | Add +11000.0% | 377,400 | $68.31 | $26M | +374,000 | +$26M |
| UTHR - United Therapeutics | 0.11% | Reduce −76.9% | 110,000 | $229.72 | $25M | −366,000 | −$79M |
| GERN - Geron | 0.11% | New | 7,495,000 | $3.30 | $25M | +7,495,000 | +$25M |
| BABA - Alibaba Group | 0.11% | Reduce −38.5% | 329,000 | $72.36 | $24M | −206,000 | −$18M |
| PGNY - Progyny | 0.10% | New | 592,600 | $38.15 | $23M | +592,600 | +$23M |
| VYGR - Voyager Therapeutics | 0.10% | Add +77.4% | 2,292,000 | $9.31 | $21M | +1,000,000 | +$10M |
| PCG - Pg And E | 0.10% | Reduce −44.0% | 1,271,642 | $16.76 | $21M | −1,000,000 | −$20M |
| APGE - Apogee Therapeutics | 0.09% | New | 305,000 | $66.45 | $20M | +305,000 | +$20M |
| Elevation Oncology | 0.09% | New | 3,886,663 | $5.13 | $20M | +3,886,663 | +$20M |
| HUM - Humana | 0.08% | Reduce −57.4% | 51,700 | $346.72 | $18M | −69,644 | −$38M |
| SYRE - Spyre Therapeutics | 0.08% | New | 466,000 | $37.93 | $18M | +466,000 | +$18M |
| ARQT - Arcutis Biotherapeutics | 0.08% | New | 1,780,000 | $9.91 | $18M | +1,780,000 | +$18M |
| Ventyx Biosciences | 0.08% | New | 3,170,000 | $5.50 | $17M | +3,170,000 | +$17M |
| Zymeworks | 0.08% | Reduce −8.8% | 1,601,000 | $10.52 | $17M | −155,000 | −$1M |
| ASND - Ascendis Pharma A/S | 0.07% | New | 109,000 | $151.17 | $16M | +109,000 | +$16M |
| Intra-Cellular Therapies | 0.07% | New | 231,000 | $69.20 | $16M | +231,000 | +$16M |
| TAL - Tal Education Group | 0.07% | Hold | 1,365,000 | $11.35 | $15M | — | — |
| RNAGBP - Avidity Biosciences | 0.07% | New | 606,061 | $25.52 | $15M | +606,061 | +$15M |
| Immunome | 0.07% | New | 594,000 | $24.68 | $15M | +594,000 | +$15M |
| Metagenomi | 0.06% | New | 1,343,201 | $10.55 | $14M | +1,343,201 | +$14M |
| PACB — | 0.06% | Reduce −39.1% | 3,772,452 | $3.75 | $14M | −2,418,918 | −$47M |
| Savara | 0.05% | Reduce −61.7% | 2,394,299 | $4.98 | $12M | −3,861,107 | −$17M |
| QTRX - Quanterix | 0.05% | Add +156.0% | 471,000 | $23.56 | $11M | +287,000 | +$6M |
| Screaming Eagle Acquisitn · CLASS A | 0.05% | Hold | 1,000,000 | $10.70 | $11M | — | — |
| ROIV - Roivant Sciences | 0.04% | Reduce −87.8% | 898,600 | $10.54 | $9M | −6,437,400 | −$73M |
| RIO - Rio Tinto | 0.04% | Hold | 137,500 | $63.74 | $9M | — | — |
| Cazoo Group · CL A | 0.04% | Hold | 714,240 | $12.00 | $9M | — | — |
| BRKR - Bruker | 0.04% | Add +2670.0% | 83,100 | $93.94 | $8M | +80,100 | +$8M |
| Gossamer Bio | 0.03% | Hold | 6,130,272 | $1.18 | $7M | — | — |
| CYTK - Cytokinetics | 0.03% | Reduce −90.6% | 102,400 | $70.11 | $7M | −985,372 | −$84M |
| Helix Acquisition Ii · CL A | 0.03% | New | 600,000 | $10.35 | $6M | +600,000 | +$6M |
| NVAX - Novavax | 0.02% | New | 1,131,000 | $4.78 | $5M | +1,131,000 | +$5M |
| PRME - Prime Medicine | 0.02% | New | 750,000 | $7.00 | $5M | +750,000 | +$5M |
| ALT - Altimmune | 0.02% | Add +1282.4% | 470,000 | $10.18 | $5M | +436,000 | +$4M |
| GDS — | 0.02% | New | 710,000 | $6.65 | $5M | +710,000 | +$5M |
| RARE — | 0.02% | New | 99,000 | $46.69 | $5M | +99,000 | +$5M |
| CNTA - Centessa Pharmaceuticals | 0.02% | New | 371,000 | $11.30 | $4M | +371,000 | +$4M |
| AMLX - Amylyx Pharmaceuticals | 0.01% | New | 1,150,221 | $2.84 | $3M | +1,150,221 | +$3M |
| Swiftmerge Acquisition · CLASS A | 0.01% | Hold | 300,000 | $10.82 | $3M | — | — |
| COGT - Cogent Biosciences | 0.01% | Add +2617.6% | 462,000 | $6.72 | $3M | +445,000 | +$3M |
| PRAX — | 0.01% | New | 50,000 | $61.02 | $3M | +50,000 | +$3M |
| Berenson Acquisition I · CL A | 0.01% | Hold | 285,715 | $10.35 | $3M | — | — |
| AVBP - Arrivent Biopharma | 0.01% | New | 151,768 | $17.86 | $3M | +151,768 | +$3M |
| Arya Sciences Acqu Iv · CL A | 0.01% | Hold | 200,000 | $11.27 | $2M | — | — |
| Metals Acquisition | 0.01% | Hold | 157,500 | $12.85 | $2M | — | — |
| Summit Midstream Partners | 0.01% | Hold | 58,214 | $28.07 | $2M | — | — |
| Marblegate Acquisition · CL A | 0.01% | Hold | 150,000 | $10.46 | $2M | — | — |
| Cara Therapeutics | 0.01% | Hold | 1,556,251 | $0.9100 | $1M | — | — |
| Forte Biosciences | 0.01% | Hold | 1,810,455 | $0.7007 | $1M | — | — |
| SLNOEUR - Soleno Therapeutics | 0.01% | Reduce −83.2% | 27,750 | $42.80 | $1M | −137,469 | −$5M |
| VNET - VNET Group | 0.00% | Reduce −63.4% | 650,000 | $1.55 | $1M | −1,125,000 | −$4M |
| MDGL - Madrigal Pharmaceuticals | 0.00% | Hold | 3,319 | $267.04 | $886K | — | — |
| Sage Therapeutics | 0.00% | Hold | 42,800 | $18.74 | $802K | — | — |
| Lufax | 0.00% | Hold | 149,999 | $4.22 | $633K | — | — |
| IOVA - Iovance Biotherapeutics | 0.00% | Reduce −95.4% | 26,000 | $14.82 | $385K | −536,000 | −$4M |
| Blueprint Medicines | 0.00% | Hold | 4,000 | $94.86 | $379K | — | — |
| KRYS - Krystal Biotech | 0.00% | Hold | 2,000 | $177.93 | $356K | — | — |
| APLSUSD - Apellis Pharmaceuticals | 0.00% | Hold | 6,000 | $58.78 | $353K | — | — |
| HCA - Hca Healthcare | 0.00% | Reduce −95.2% | 1,000 | $333.53 | $334K | −19,900 | −$5M |
| AXSM - Axsome Therapeutics | 0.00% | Hold | 4,000 | $79.80 | $319K | — | — |
| ALNY - Alnylam Pharmaceuticals | 0.00% | Hold | 2,000 | $149.45 | $299K | — | — |
| ACLXGBX - Arcellx | 0.00% | Hold | 4,000 | $69.55 | $278K | — | — |
| CHE - Chemed | 0.00% | Hold | 400 | $641.93 | $257K | — | — |
| EHC - Encompass Health | 0.00% | Hold | 3,000 | $82.58 | $248K | — | — |
| GKOS - Glaukos | 0.00% | Hold | 2,600 | $94.29 | $245K | — | — |
| SNDX - Syndax Pharmaceuticals | 0.00% | Hold | 10,000 | $23.80 | $238K | — | — |
| CRNX — | 0.00% | Reduce −95.9% | 5,000 | $46.81 | $234K | −117,904 | −$4M |
| ACHC — | 0.00% | Hold | 2,800 | $79.22 | $222K | — | — |
| SBRA - Sabra Health Care Reit | 0.00% | Hold | 14,000 | $14.77 | $207K | — | — |
| R1 Rcm | 0.00% | Hold | 16,000 | $12.88 | $206K | — | — |
| AM6 - Amicus Therapeutics | 0.00% | Hold | 16,000 | $11.78 | $188K | — | — |
Showing top 50 of 124 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| CHTR - Charter Communications · CL A | 1.54% | Exit | 0 | $388.68 | $311M | −799,141 | −$311M |
| BX - Blackstone | 1.10% | Exit | 0 | $130.92 | $222M | −1,697,351 | −$222M |
| Mirati Therapeutics | 0.59% | Exit | 0 | $58.75 | $119M | −2,024,472 | −$119M |
| Catalent | 0.32% | Exit | 0 | $44.93 | $63M | −1,413,000 | −$63M |
| Immunogen | 0.12% | Exit | 0 | $29.65 | $25M | −842,000 | −$25M |
| Holding | 0.12% | Exit | 0 | $42.40 | $24M | −567,321 | −$24M |
| VRTX - Vertex Pharmaceuticals | 0.11% | Exit | 0 | $406.89 | $22M | −55,000 | −$22M |
| OPCH - Option Care Health | 0.09% | Exit | 0 | $33.69 | $19M | −567,800 | −$19M |
| IMVT - Immunovant | 0.07% | Exit | 0 | $42.13 | $14M | −341,000 | −$14M |
| TVTX - Travere Therapeutics | 0.05% | Exit | 0 | $8.99 | $10M | −1,094,000 | −$10M |
| NBIX - Neurocrine Biosciences | 0.05% | Exit | 0 | $131.76 | $10M | −72,398 | −$10M |
| Gores Ix · CLASS A | 0.03% | Exit | 0 | $10.50 | $5M | −500,000 | −$5M |
| Bluebird Bio | 0.01% | Exit | 0 | $1.38 | $3M | −2,000,000 | −$3M |
| CRL - Charles Riv Labs Intl | — | Exit | 0 | $236.50 | $473K | −2,000 | −$473K |
| BNTX - Biontech Se | — | Exit | 0 | $105.62 | $406K | −3,844 | −$406K |
| BBIO - Bridgebio Pharma | — | Exit | 0 | $40.33 | $242K | −6,000 | −$242K |
| MLTX - Moonlake Immunotherapeutics · CLASS A | — | Exit | 0 | $60.29 | $205K | −3,400 | −$205K |
| IART — | — | Exit | 0 | $43.48 | $200K | −4,600 | −$200K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
FARALLON CAPITAL MANAGEMENT, L.L.C.
87 processed 13Fs on this site · 2021 Q3–2026 Q2